Money laundering probe at Fontainebleau mistakenly disclosed by Gaming Commission
(Photo byfor Fontainebleau Las Vegas)
An inadvertent leak at Thursday's Nevada Gaming Commission meeting revealed Fontainebleau, the newest resort on the Las Vegas Strip, is under investigation by gaming regulators.
Nevada Gaming Commissioner Rosa Solis Rainey asked Fontainebleau president Maurice Wooden about the investigation Thursday, catching the executive off guard as he sought licensing as a key employee.
'With respect to AML (anti-money laundering), tell me about the issues that are currently going on at the Fontainebleau with respect to credit issuance,' Solis-Rainey said to Wooden. 'Are you aware of those?'
'I'm not sure of any investigation as it relates to anything with AML. Is there something specific? I'm not sure,' Wooden responded.
'I think that is something that staff is currently further investigating, prior to any further action,' Gaming Control Board member Chandeni Sendall chimed in.
'It's not listed in our materials as confidential, by the way,' noted a visibly irked Gaming Commission Chairwoman Jennifer Togliatti.
'Is it confidential or not confidential?' Solis-Rainey inquired. 'We have in our materials that there's an investigation ongoing with respect to the credit practices not being followed.'
The issue, she said, involved ownership approving credit without proper approval from compliance executives. Fontainebleau is owned by Jeffrey Soffer. The $3.7 billion property opened in December 2023.
'If those processes happened, they were certainly before my time. I was, you know, not on property for what I believe some of the questions you're asking,' Wooden responded, adding he believes 'at least one or two of those issues did happen, almost like the opening week.'
Wooden is likely referring to a $2 million marker issued to gambler and illegal bookmaker Damien LeForbes, shortly after the resort's opening in December 2023, according to Robert Cipriani, a professional gambler who provided information to the federal government about money laundering at MGM Grand and Resorts World.
LeForbes and illegal sports bookie Mathew Bowyer have pleaded guilty to operating unlawful gambling businesses and to money laundering.
MGM Resorts entered into a non-prosection agreement with the government in early 2024 and paid a $7.45 million fine. Its former president, Scott Sibella, agreed to a plea deal for failing to comply with AML regulations. The feds have yet to take any action against Resorts World, where Sibella also served as president until his termination in September of 2023, and where Bowyer and LeForbes were permitted to gamble without known sources of funds.
The Gaming Commission fined Resorts World $10.5 million in March and imposed an $8.5 million fine against MGM in April.
Cipriani contends the investigation has expanded to a handful of other resorts, including Fontainebleau.
In early January 2024, weeks after Fontainebleau's opening, Cipriani tweeted the casino granted a $2 million marker to LeForbes, who eventually 'blew thru it all,' according to Cipriani.
'All the casinos that took DJ Leforbes' and Matt Bowyer's action are being investigated by GCB,' Cipriani said Friday.
No efforts have been made by Fontainebleau or Venetian, where the two also gambled, to recover the funds via the District Attorney's Office, according to court records.
Gaming Control Board Chairman Kirk Hendrick told Togliatti the information about the investigation, which was included in the Commission's back up documents, should have been marked confidential.
'I don't want to go any deeper into this matter until the board has an opportunity to review it and, of course, speak with the licensee,' he said.
Stacy Michaels, a Fontainebleau executive, said the GCB audited five player accounts and had concerns with three. Michaels added that agents were eventually satisfied the company had followed proper protocol.
The Gaming Commission issued a two-year license to Wooden.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN FRANSCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the first patient in its Phase 1 clinical trial of CER-1236. The patient was dosed at the lead trial site in a study focused on patients with acute myeloid leukemia (AML). Now more than seven days post-infusion, monitoring continues for key safety, tolerability, and efficacy endpoints. The study will be featured in a poster being presented at the 2025 Annual Meeting of the American Society of Clinical Oncology being held in Chicago May 30-June 3, 2025. Abhishek Maiti, M.D., assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center, is the lead investigator of the trial. He worked with Cero team on publishing the novel preclinical data in Clinical Cancer Research. The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study has begun with dose escalation to determine the highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK). Robert Sikorski, M.D. Ph.D., CERo Therapeutics' Chief Medical Officer remarked, 'The completion of first-in-human dosing represents a clinical development milestone for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L. Protocol-specified evaluations of safety, pharmacodynamic, pharmacokinetic, and efficacy endpoints are in progress. We look forward to communicating results as data matures.' A peer-reviewed manuscript with robust preclinical data was published earlier in Clinical Cancer Research. The Company is presenting a poster that outlines the Phase 1/1b study at the American Society of Clinical Oncology 2025 Annual Meeting in Chicago May 30-June 3, 2025 at Chicago's McCormick Place Convention Center. The abstract for the poster, titled, 'First in human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-L in acute myeloid leukemia (CertainT-1)' can be found here. The poster session, at which Dr. Sikorski will be present, is being held June 1st, and is titled, 'Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes and Allotransplant.' CERo CEO Chris Ehrlich concluded, 'We are grateful for the participation of our first patient and to the many people who have worked tirelessly to reach this milestone, including our CERO team, our consultants and study sites. We look forward to discussing additional outcomes, which we continue to believe will validate the scientific work performed to date with CER-1236.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:Chris EhrlichChief Executive Officerchris@ Investors:CORE IR investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
20 hours ago
- Business Upturn
Esthen Exchange Launches Global Upgrade to Strengthen DeFi and Security Infrastructure
Denver, CO, May 29, 2025 (GLOBE NEWSWIRE) — Esthen Exchange has announced a major upgrade to its digital asset trading infrastructure, reinforcing its role as a secure and scalable platform in the decentralized finance (DeFi) sector. The new release combines high-speed execution, advanced compliance architecture, and DeFi-focused product expansion to support the next stage of global digital finance. The platform now delivers sub-millisecond order execution through a proprietary matching engine, ensuring resilience under high-volume trading conditions. This technical enhancement is integrated with a full-stack DeFi interface, enabling seamless access to decentralized lending, staking, liquidity mining, and token markets from a single gateway. Security remains a foundational principle. Esthen Exchange utilizes cold-hot wallet segregation, multi-signature authorization, encrypted data channels, and AI-based anomaly detection systems to safeguard platform operations. A round-the-clock surveillance layer monitors all transactional behavior to mitigate risks in real time. The platform maintains a strong compliance posture, enforcing global KYC and AML protocols through jurisdictional teams across Asia, Europe, and the Americas. This structure enables secure onboarding, custody, and service delivery in accordance with evolving regional regulations. Esthen Exchange continues to expand its asset listing capabilities, supporting a decentralized onboarding framework that allows high-potential blockchain projects to be integrated efficiently. Verified listings are backed by cross-chain compatibility assessments and liquidity provisioning criteria. Beyond trading, Esthen provides multilingual access, fiat gateways, and a structured education system. The platform's analytics suite offers chain-level data, performance metrics, and portfolio insights to support both new and advanced users in their decision-making process. 'Esthen Exchange is committed to building intelligent, secure infrastructure for the decentralized economy,' said Zachary Ward, Chief Strategy Officer at Esthen Exchange. 'This upgrade reflects a long-term vision of open, data-driven finance that bridges traditional and digital asset models.' Esthen's roadmap includes DAO governance deployment, RWA clearing tools, and further integration of Web3 identity systems. Through infrastructure refinement and compliance scalability, Esthen Exchange aims to redefine how digital capital moves across borders and protocols. About Esthen Exchange Esthen Exchange is a global digital asset trading platform that provides secure, high-performance infrastructure for cryptocurrency trading, DeFi integration, and real-world asset connectivity. With multi-layered security, jurisdictional compliance, and a user-centric product suite, Esthen serves as a trusted entry point for institutional and retail investors across the decentralized economy. Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.


Business Wire
a day ago
- Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndromes (MDS). Mesutoclax is an important global asset of InnoCare in the field of hematology. This approval marks the Company will initiate the clinical trial for the fourth indication of our BCL2 inhibitor. Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years). Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible.' About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.